New Preclinical Data Demonstrate Potential of Capsida’s IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations

Data to be featured as oral and poster presentations at American Epilepsy Society 2024 Annual Meeting THOUSAND OAKS, Calif., Dec. 6, 2024 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”) today announced new preclinical data on CAP-002, its first-in-class IV-administered next-generation…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.